Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Denali Therapeutics Inc (NASDAQ: DNLI) closed at $14.7 in the last session, up 1.66% from day before closing price of $14.46. In other words, the price has increased by $1.66 from its previous closing price. On the day, 1.15 million shares were traded. DNLI stock price reached its highest trading level at $14.95 during the session, while it also had its lowest trading level at $14.44.
Ratios:
We take a closer look at DNLI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.27 and its Current Ratio is at 10.27. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $31.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $31 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 12 ’25 when Schuth Alexander O. sold 2,937 shares for $13.58 per share. The transaction valued at 39,884 led to the insider holds 242,346 shares of the business.
Ho Carole sold 2,937 shares of DNLI for $39,884 on Aug 12 ’25. The Chief Medical Officer now owns 217,391 shares after completing the transaction at $13.58 per share. On Aug 13 ’25, another insider, Ho Carole, who serves as the Chief Medical Officer of the company, sold 806 shares for $14.64 each. As a result, the insider received 11,800 and left with 216,585 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 2149316352 and an Enterprise Value of 1667918720.
Stock Price History:
The Beta on a monthly basis for DNLI is 1.23, which has changed by -0.3862213 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, DNLI has reached a high of $33.33, while it has fallen to a 52-week low of $10.57. The 50-Day Moving Average of the stock is 2.78%, while the 200-Day Moving Average is calculated to be -18.67%.
Shares Statistics:
According to the various share statistics, DNLI traded on average about 1.60M shares per day over the past 3-months and 1949850 shares per day over the past 10 days. A total of 145.69M shares are outstanding, with a floating share count of 126.49M. Insiders hold about 13.49% of the company’s shares, while institutions hold 93.92% stake in the company. Shares short for DNLI as of 1753920000 were 12830063 with a Short Ratio of 8.04, compared to 1751241600 on 12457321. Therefore, it implies a Short% of Shares Outstanding of 12830063 and a Short% of Float of 9.8900005.
Earnings Estimates
The current rating of Denali Therapeutics Inc (DNLI) reflects the combined expertise of 15.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.38 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$2.64 and -$3.3 for the fiscal current year, implying an average EPS of -$3.01. EPS for the following year is -$2.82, with 14.0 analysts recommending between -$1.81 and -$3.68.
Revenue Estimates
Based on 18 analysts’ estimates, the company’s revenue will be $86.78M in the next fiscal year. The high estimate is $278.66M and the low estimate is $9.56M.
